Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform

References

• Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64:529-64; PMID:7724661; http://dx.doi.org/10.1016/0163-7258(94)90023-X
   PubMed Web of Science ®Google Scholar
• Tsung K, Norton JA. Lessons from Coley's toxin. Surg Oncol 2006; 15:25-8; PMID:16814541; http://dx.doi.org/10.1016/j.suronc.2006.05.002
   PubMed Web of Science ®Google Scholar
• Smyth MJ, Teng MW. Targeting the IL-12/IL-23 axis: An alternative approach to removing tumor induced immune suppression. Onco Immunol 2014; 3:e28964; PMID:25083324
   PubMedGoogle Scholar
• Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012; 12:278-87; PMID:22437872; http://dx.doi.org/10.1038/nrc3236
   PubMed Web of Science ®Google Scholar
• Nguyen DM, Schrump DS. Growth factor receptors as targets for lung cancer therapy. Semin Thorac Cardiovasc Surg 2004; 16:3-12; PMID:15366682; http://dx.doi.org/10.1053/j.semtcvs.2003.12.002
   PubMedGoogle Scholar
• Negro A, Brar BK, Lee KF. Essential roles of Her2/erbB2 in cardiac development and function. Recent Prog Horm Res 2004; 59:1-12; PMID:14749494; http://dx.doi.org/10.1210/rp.59.1.1
   PubMedGoogle Scholar
• Mortus JR, Zhang Y, Hughes DP. Developmental pathways hijacked by osteosarcoma. Adv Exp Med Biol 2014; 804:93-118; PMID:24924170; http://dx.doi.org/10.1007/978-3-319-04843-7_5
   PubMed Web of Science ®Google Scholar
• Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell 2014; 25:282-303; PMID:24651011; http://dx.doi.org/10.1016/j.ccr.2014.02.025
   PubMed Web of Science ®Google Scholar
• Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol 2014; 15:e58-68; PMID:24480556; http://dx.doi.org/10.1016/S1470-2045(13)70477-7
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 2007; 357:39-51; PMID:17611206; http://dx.doi.org/10.1056/NEJMra043186
   PubMed Web of Science ®Google Scholar
• Sabatier R, Goncalves A. Pertuzumab (Perjeta) approval in HER2-positive metastatic breast cancers. Bull Cancer 2014; 101:765-71; PMID:25091659; http://dx.doi.org/10.1684/bdc.2014.1940
   PubMed Web of Science ®Google Scholar
• Leveque D, Gigou L, Bergerat JP. Clinical pharmacology of trastuzumab. Curr Clin Pharmacol 2008; 3:51-5; PMID:18690878; http://dx.doi.org/10.2174/157488408783329931
   PubMedGoogle Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006; 11:81-8; PMID:16478695; http://dx.doi.org/10.1016/S1359-6446(05)03638-X
   PubMed Web of Science ®Google Scholar
• Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 23:2162-71; PMID:15800309; http://dx.doi.org/10.1200/JCO.2005.01.014
   PubMed Web of Science ®Google Scholar
• Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol 2014; 74:819-29; PMID:25119184; http://dx.doi.org/10.1007/s00280-014-2560-3
   PubMed Web of Science ®Google Scholar
• Leyland-Jones B. Dose scheduling–Herceptin. Oncology 2001; 61 Suppl 2:31-6; PMID:11694785; http://dx.doi.org/10.1159/000055399
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N Engl J Med 2008; 358:1109-17; PMID:18337601; http://dx.doi.org/10.1056/NEJMoa074943
   PubMed Web of Science ®Google Scholar
• Maier S, Chung CH, Morse M, Platts-Mills T, Townes L, Mukhopadhyay P, Bhagavatheeswaran P, Racenberg J, Trifan OC. A retrospective analysis of cross-reacting cetuximab IgE antibody and its association with severe infusion reactions. Cancer Med 2014; 4(1):36-42; PMID:25296628; http://dx.doi.org/10.1002/cam4.333. Epub 2014 Oct 9
   PubMed Web of Science ®Google Scholar
• Hsu Blatman KS, Castells MC. Desensitizations for chemotherapy and monoclonal antibodies: indications and outcomes. Curr Allergy Asthma Rep 2014; 14:453; PMID:24994467; http://dx.doi.org/10.1007/s11882-014-0453-5
   PubMed Web of Science ®Google Scholar
• Castells M, Sancho-Serra Mdel C, Simarro M. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization. Cancer Immunol Immunother 2012; 61:1575-84; PMID:22576054; http://dx.doi.org/10.1007/s00262-012-1273-x
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Castells MC. Hypersensitivity reactions to biologic agents. Immunol Allergy Clin North Am 2014; 34:615-32, ix; PMID:25017680; http://dx.doi.org/10.1016/j.iac.2014.04.008
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Singer J. Cancer vaccines inducing antibody production: more pros than cons. Expert Rev Vaccines 2011; 10:1281-9; PMID:21919618; http://dx.doi.org/10.1586/erv.11.105
   PubMed Web of Science ®Google Scholar
• Sternlicht MD. Key stages in mammary gland development: the cues that regulate ductal branching morphogenesis. Breast Cancer Res 2006; 8:201; PMID:16524451; http://dx.doi.org/10.1186/bcr1368
   PubMed Web of Science ®Google Scholar
• Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 2006; 41:228-35; PMID:16769082; http://dx.doi.org/10.1016/j.yjmcc.2006.04.007
   PubMed Web of Science ®Google Scholar
• Wadugu B, Kuhn B. The role of neuregulin/ErbB2/ErbB4 signaling in the heart with special focus on effects on cardiomyocyte proliferation. Am J Physiol Heart Circ Physiol 2012; 302:H2139-47; PMID:22427524; http://dx.doi.org/10.1152/ajpheart.00063.2012
   PubMedGoogle Scholar
• Knittelfelder R, Riemer AB, Jensen-Jarolim E. Mimotope vaccination–from allergy to cancer. Expert Opin Biol Ther 2009; 9:493-506; PMID:19344285; http://dx.doi.org/10.1517/14712590902870386
   PubMed Web of Science ®Google Scholar
• Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E. High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother 2005; 54:677-84; PMID:15565329; http://dx.doi.org/10.1007/s00262-004-0632-7
   PubMed Web of Science ®Google Scholar
• Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst 2005; 97:1663-70; PMID:16288119; http://dx.doi.org/10.1093/jnci/dji373
   PubMed Web of Science ®Google Scholar
• Riemer AB, Forster-Waldl E, Bramswig KH, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes. Eur J Immunol 2006; 36:1267-74; PMID:16568495; http://dx.doi.org/10.1002/eji.200535279
   PubMed Web of Science ®Google Scholar
• Bramswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC et al. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res 2007; 13:6501-8; PMID:17975163; http://dx.doi.org/10.1158/1078-0432.CCR-07-0692
   PubMed Web of Science ®Google Scholar
• Riemer AB, Jensen-Jarolim E. Mimotope vaccines: epitope mimics induce anti-cancer antibodies. Immunol Lett 2007; 113:1-5; PMID:17825923; http://dx.doi.org/10.1016/j.imlet.2007.07.008
   PubMed Web of Science ®Google Scholar
• Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res 2007; 67:3406-11; PMID:17409451; http://dx.doi.org/10.1158/0008-5472.CAN-06-3758
   PubMed Web of Science ®Google Scholar
• Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E. Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004; 173:394-401; PMID:15210798; http://dx.doi.org/10.4049/jimmunol.173.1.394
   PubMed Web of Science ®Google Scholar
• Li X, Cao H, Wang Q, Di B, Wang M, Lu J, Pan L, Yang L, Mei M, Pan X et al. Novel AAV-based genetic vaccines encoding truncated dengue virus envelope proteins elicit humoral immune responses in mice. Microbes Infect 2012; 14:1000-7; PMID:22626929; http://dx.doi.org/10.1016/j.micinf.2012.05.002
   PubMed Web of Science ®Google Scholar
• Sipo I, Knauf M, Fechner H, Poller W, Planz O, Kurth R, Norley S. Vaccine protection against lethal homologous and heterologous challenge using recombinant AAV vectors expressing codon-optimized genes from pandemic swine origin influenza virus (SOIV). Vaccine 2011; 29:1690-9; PMID:21195079; http://dx.doi.org/10.1016/j.vaccine.2010.12.037
   PubMed Web of Science ®Google Scholar
• Nieto K, Salvetti A. AAV Vectors Vaccines Against Infectious Diseases. Front Immunol 2014; 5:5; PMID:24478774; http://dx.doi.org/10.3389/fimmu.2014.00005
   PubMed Web of Science ®Google Scholar
• McCarty DM. Self-complementary AAV vectors; advances and applications. Mol Ther 2008; 16:1648-56; PMID:18682697; http://dx.doi.org/10.1038/mt.2008.171
   PubMed Web of Science ®Google Scholar
• Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21:583-93; PMID:18854481; http://dx.doi.org/10.1128/CMR.00008-08
   PubMed Web of Science ®Google Scholar
• Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984; 81:6466-70; PMID:6093102; http://dx.doi.org/10.1073/pnas.81.20.6466
   PubMed Web of Science ®Google Scholar
• Zacchigna S, Zentilin L, Giacca M. Adeno-associated virus vectors as therapeutic and investigational tools in the cardiovascular system. Circ Res 2014; 114:1827-46; PMID:24855205; http://dx.doi.org/10.1161/CIRCRESAHA.114.302331
   PubMed Web of Science ®Google Scholar
• Bourdenx M, Dutheil N, Bezard E, Dehay B. Systemic gene delivery to the central nervous system using Adeno-associated virus. Front Mol Neurosci 2014; 7:50; PMID:24917785; http://dx.doi.org/10.3389/fnmol.2014.00050
   PubMed Web of Science ®Google Scholar
• Dai J, Rabie AB. The use of recombinant adeno-associated virus for skeletal gene therapy. Orthod Craniofac Res 2007; 10:1-14; PMID:17284242; http://dx.doi.org/10.1111/j.1601-6343.2007.00381.x
   PubMed Web of Science ®Google Scholar
• Muzyczka N, Warrington KH, Jr. Custom adeno-associated virus capsids: the next generation of recombinant vectors with novel tropism. Hum Gene Ther 2005; 16:408-16; PMID:15871672; http://dx.doi.org/10.1089/hum.2005.16.408
   PubMed Web of Science ®Google Scholar
• Nieto K, Weghofer M, Sehr P, Ritter M, Sedlmeier S, Karanam B, Seitz H, Müller M, Kellner M, Hörer M et al. Development of AAVLP(HPV16/31L2) particles as broadly protective HPV vaccine candidate. PLoS One 2012; 7:e39741; PMID:22761884; http://dx.doi.org/10.1371/journal.pone.0039741
   PubMed Web of Science ®Google Scholar
• Chang C, Takayanagi A, Yoshida T, Shimizu N. Recombinant human IgG antibodies recognizing distinct extracellular domains of EGF receptor exhibit different degrees of growth inhibitory effects on human A431 cancer cells. Exp Cell Res 2013; 319:1146-55; PMID:23499740; http://dx.doi.org/10.1016/j.yexcr.2013.03.002
   PubMed Web of Science ®Google Scholar
• Barutello G, Curcio C, Spadaro M, Arigoni M, Trovato R, Bolli E, Zheng Y, Ria F, Quaglino E, Iezzi M et al. Antitumor immunization of mothers delays tumor development in cancer-prone offspring. Onco Immunol 2015; 4:e1005500; PMID:26155401; http://dx.doi.org/10.1080/2162402X.2015.1005500
   PubMedGoogle Scholar
• Michaud HA, Eliaou JF, Lafont V, Bonnefoy N, Gros L. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. Onco Immunol 2014; 3:e955684
   Google Scholar
• Spel L, Boelens JJ, Nierkens S, Boes M. Antitumor immune responses mediated by dendritic cells: How signals derived from dying cancer cells drive antigen cross-presentation. Onco Immunol 2013; 2:e26403; PMID:24482744; http://dx.doi.org/10.4161/onci.26403
   PubMedGoogle Scholar
• Buonaguro L, Tagliamonte M, Visciano ML, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for HIV. Expert Rev Vaccines 2013; 12:119-27; PMID:23414404; http://dx.doi.org/10.1586/erv.12.152
   PubMed Web of Science ®Google Scholar
• Platzer B, Elpek KG, Cremasco V, Baker K, Stout MM, Schultz C, Dehlink E, Shade KT, Anthony RM, Blumberg RS et al. IgE/FcepsilonRI-mediated antigen cross-presentation by dendritic cells enhances anti-tumor immune responses. Cell Rep 2015; S2211-1247(15):00143-6; PMID:25753415; http://dx.doi.org/10.1016/j.celrep.2015.02.015
   PubMedGoogle Scholar
• Hafner C, Wagner S, Allwardt D, Riemer AB, Scheiner O, Pehamberger H, Breiteneder H. Cross-reactivity of mimotopes with a monoclonal antibody against the high molecular weight melanoma-associated antigen (HMW-MAA) does not predict cross-reactive immunogenicity. Melanoma Res 2005; 15:111-7; PMID:15846144; http://dx.doi.org/10.1097/00008390-200504000-00005
   PubMed Web of Science ®Google Scholar
• Schulte S, Sukhova GK, Libby P. Genetically programmed biases in Th1 and Th2 immune responses modulate atherogenesis. Am J Pathol 2008; 172:1500-8; PMID:18467709; http://dx.doi.org/10.2353/ajpath.2008.070776
   PubMed Web of Science ®Google Scholar
• Fukushima A, Yamaguchi T, Ishida W, Fukata K, Taniguchi T, Liu FT, Ueno H. Genetic background determines susceptibility to experimental immune-mediated blepharoconjunctivitis: comparison of Balb/c and C57BL/6 mice. Exp Eye Res 2006; 82:210-8; PMID:16102751; http://dx.doi.org/10.1016/j.exer.2005.06.010
   PubMed Web of Science ®Google Scholar
• Petrovsky N, Aguilar JC. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 2004; 82:488-96; PMID:15479434; http://dx.doi.org/10.1111/j.0818-9641.2004.01272.x
   PubMed Web of Science ®Google Scholar
• Wheeler AW, Marshall JS, Ulrich JT. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. Int Arch Allergy Immunol 2001; 126:135-9; PMID:11729351; http://dx.doi.org/10.1159/000049504
   PubMed Web of Science ®Google Scholar
• Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160:3627-30; PMID:9558060
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12:341-55; PMID:21499295; http://dx.doi.org/10.1038/nrg2988
   PubMed Web of Science ®Google Scholar
• Dismuke DJ, Tenenbaum L, Samulski RJ. Biosafety of recombinant adeno-associated virus vectors. Curr Gene Ther 2013; 13:434-52; PMID:24195602; http://dx.doi.org/10.2174/15665232113136660007
   PubMed Web of Science ®Google Scholar
• Flotte TR, Berns KI. Adeno-associated virus: a ubiquitous commensal of mammals. Hum Gene Ther 2005; 16:401-7; PMID:15871671; http://dx.doi.org/10.1089/hum.2005.16.401
   PubMed Web of Science ®Google Scholar
• Manzano-Szalai K, Thell K, Willensdorfer A, Weghofer M, Pfanzagl B, Singer J, Ritter M, Stremnitzer C, Flaschberger I, Michaelis U et al. Adeno-associated virus-like particles as new carriers for B-cell vaccines: testing immunogenicity and safety in BALB/c mice. Viral Immunol 2014; 27:438-48; PMID:25247267; http://dx.doi.org/10.1089/vim.2014.0059
   PubMed Web of Science ®Google Scholar
• Lasfargues EY, Coutinho WG, Redfield ES. Isolation of two human tumor epithelial cell lines from solid breast carcinomas. J Natl Cancer Inst 1978; 61:967-78; PMID:212572
   PubMedGoogle Scholar
• Mahoney KH, Miller BE, Heppner GH. FACS quantitation of leucine aminopeptidase and acid phosphatase on tumor-associated macrophages from metastatic and nonmetastatic mouse mammary tumors. J Leukoc Biol 1985; 38:573-85; PMID:2413152
   PubMed Web of Science ®Google Scholar
• Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B, Heilbrun L, Jones RF. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81:748-54; PMID:10328228; http://dx.doi.org/10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW, Jr, Leahy DJ. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421:756-60; PMID:12610629; http://dx.doi.org/10.1038/nature01392
   PubMed Web of Science ®Google Scholar
• Veldwijk MR, Topaly J, Laufs S, Hengge UR, Wenz F, Zeller WJ, Fruehauf S. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002; 6:272-8; PMID:12349826; http://dx.doi.org/10.1006/mthe.2002.0659
   PubMed Web of Science ®Google Scholar
• Wu P, Xiao W, Conlon T, Hughes J, Agbandje-McKenna M, Ferkol T, Flotte T, Muzyczka N. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J Virol 2000; 74:8635-47; PMID:10954565; http://dx.doi.org/10.1128/JVI.74.18.8635-8647.2000
   PubMed Web of Science ®Google Scholar
• Kneitz RH, Schubert J, Tollmann F, Zens W, Hedman K, Weissbrich B. A new method for determination of varicella-zoster virus immunoglobulin G avidity in serum and cerebrospinal fluid. BMC Infect Dis 2004; 4:33; PMID:15355548; http://dx.doi.org/10.1186/1471-2334-4-33
   PubMed Web of Science ®Google Scholar
• Horer M, Hallek M. Method for producing a recombinant adeno-associated virus, suitable means therefor and use for producing a medicament. Google Patents 2005.
   Google Scholar
• Buening H, Nieland J, Perabo L, Goldnau D, Lux K, Hallek M et al. Mutated parvovirus structural proteins as vaccines. Google Patents 2008.
   Google Scholar
• Corpet F. Multiple sequence alignment with hierarchical clustering. Nucleic Acids Res 1988; 16:10881-90; PMID:2849754; http://dx.doi.org/10.1093/nar/16.22.10881
   PubMed Web of Science ®Google Scholar